Non-conventional use of growth hormone: European experience.
Results from several centres in Europe using biosynthetic human growth hormone (hGH) for the promotion of growth in a variety of conditions other than classical hGH deficiency were evaluated. Significant increments in growth rates were achieved by daily administration of hGH in doses appropriate for body size without disproportionate skeletal advances in short normals, Turner syndrome, low birth weight, skeletal dysplasia, central precocious puberty (reared with gonadotrophin-releasing hormone analogue) and renal failure.
Darendeliler
F
F
Endocrine Unit, Middlesex Hospital, London, UK.
Hindmarsh
P C
PC
Brook
C G
CG
D002648:Child; D002908:Chronic Disease; D005060:Europe; D006130:Growth Disorders / Q000188:drug therapy; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D010009:Osteochondrodysplasias / Q000188:drug therapy; D011628:Puberty, Delayed / Q000188:drug therapy; D011629:Puberty, Precocious / Q000188:drug therapy; D014424:Turner Syndrome / Q000188:drug therapy
D013006:Growth Hormone